| Followers | 1 |
| Posts | 43 |
| Boards Moderated | 0 |
| Alias Born | 08/17/2018 |
Friday, August 24, 2018 12:55:02 PM
A voice of reason.
As a clinician I can tell you the clinical side is a long and hard one. Had 2 reps from well establish Pharm in just this AM trying to push their products. FDA approval by no means is a guarantee of success.
An example is the drug Vivitrol. Now gaining popular for opiate cravings. This medication is nothing butlong acting Nalrexone. Naltrexone has been around for decades (literally). The point is that is in most cases this is the very long game that involves racking up huge debt along the way.
Also,if you not in a Tier level good luck with getting insurance to ever pay for. If they do it will be after 3 fail trials of other peoples product.
Right now the consumer market is were it needs to focus. That is were CBD best bet is. Success in the clinical market is far out (like 10-15 years...no joke)
As a clinician I can tell you the clinical side is a long and hard one. Had 2 reps from well establish Pharm in just this AM trying to push their products. FDA approval by no means is a guarantee of success.
An example is the drug Vivitrol. Now gaining popular for opiate cravings. This medication is nothing butlong acting Nalrexone. Naltrexone has been around for decades (literally). The point is that is in most cases this is the very long game that involves racking up huge debt along the way.
Also,if you not in a Tier level good luck with getting insurance to ever pay for. If they do it will be after 3 fail trials of other peoples product.
Right now the consumer market is were it needs to focus. That is were CBD best bet is. Success in the clinical market is far out (like 10-15 years...no joke)
Recent CVSI News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 08:50:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2025 08:01:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/15/2025 09:25:41 PM
